Hiroshi Tanaka - Concepedia

Author

Hiroshi Tanaka

Also Known As

C Thompson, H Matsuda, H TANAKA, H Tanaka, H. TANAKA, H. Tanaka, HIROSHI TANAKA, HIROSHI Tanaka, Hidetsugu TANAKA, Hidetsugu Tanaka

1.3K

Publications

23.4K

Citations

H-Index

450

Concepts

All Affiliations

Hirosaki University Tokyo Medical and Dental University Hirosaki University Hospital Hokkaido University Niigata University

About

Hiroshi Tanaka is an author at Hirosaki University specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	46	197	9.8K
2	Natural Sciences	21	28	1.2K
3	Engineering	14	21	742
4	Health Sciences	13	18	939
5	Education	2	2	91

Hiroshi Tanaka

388

Publications

21.5K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok, Yi‐Long Wu, Iveta Kudaba, The Lancet	2019	3.2K
Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT Kazuhiro Sanpei, Hiroki Takano, S. Igarashi, Nature Genetics Molecular NeuroscienceDirect IdentificationCloning TechniqueGenetic DisorderMendelian Disorder	1996	771
Loss of Keap1 Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth Tsutomu Ohta, Kumiko Iijima, Mamiko Miyamoto, Cancer Research	2008	620
Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells Carsten O. Daub, Kristoffer Vitting‐Seerup, Robin Andersson, Science ChromatinTranscriptional RegulationSystems BiologyDevelopmental BiologyFunctional Genomics	2015	596
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, The Lancet Oncology MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncology	2019	594
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis Satoshi Watanabe, Junta Tanaka, Takeshi Ota, BMC Cancer	2011	392
Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell Toshifumi Yae, Kenji Tsuchihashi, Takatsugu Ishimoto, Nature Communications MedicineCd44 MrnaCancer Cell BiologyAlternative SplicingEsrp1 Enhances	2012	378
Inherited Complete Deficiency of 20-Kilodalton Homologous Restriction Factor (CD59) as a Cause of Paroxysmal Nocturnal Hemoglobinuria Manabu Yamashina, E Ueda, Taroh Kinoshita, New England Journal of Medicine GeneticsImmunologyInherited Complete DeficiencyPathologyHeme Trafficking	1990	362
The gene for Machado–Joseph disease maps to human chromosome 14q Yoshihisa Takiyama, Masatoyo Nishizawa, Hiroshi Tanaka, Nature Genetics Chromosome DynamicsHuman Chromosome 14QCytogeneticsGenetic DisorderGenetics	1993	350
FANTOM5 CAGE profiles of human and mouse samples Shuhei Noguchi, Takahiro Arakawa, Shiro Fukuda, Scientific Data	2017	349

Page 1